Amlo Biosciences

Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients' true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.
Social Link - Twitter: https://twitter.com/AMLoBiosciences
Social Link - Linkedin: http://www. linkedin.com/company /amlo-biosciences
Employee Count: 18
Keywords: biotechnology research